Peptic ulcer disease: Defining the treatment strategies in the era of Helicobacter pylori

American Journal of Gastroenterology

Volumn 92, Issue 4, 1997, Pages

  Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ARTICLE; DRUG EFFICACY; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMPS;

EID: 0031003379     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kurata JH. Ulcer epidemiology: An overview and proposed research framework. Gastroenterology 1989;96:569-80.
2. Paringer L, Berk A. Costs of illnesses and disease, fiscal year 1975. Report No. 2, Contract No. 1-0D-5-2121. Washington, DC: Public Services Laboratory, Georgetown University, 1977.
3. Von Haunalter G, Chandler VV. Cost of ulcer disease in the United States. Stanford, CA: Stanford Research Institute, 1977. Project No. 5894.
4. Blaser MJ. Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology 1987;93:371-83.
5. Dooley CP, Cohen H. The clinical significance of Campylobacter pylori. Ann Intern Med 1988;108:70-9.
6. Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989;321:1562-6.
7. Perez-Perez GI, Dworkin BM, Chodos JE, et al. Campylobacter pylori antibodies in humans. Ann Intern Med 1988;109:11-7.
8. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991;324:1043-8.
9. Walsh JH. Acid peptic disorders of the gastrointestinal tract. In: Kelley WN, DeVita VT Jr, eds. Textbook of internal medicine, 2nd ed. Philadelphia: Lippincott, 1992: 500-13.
10. Soll AH. Gastric, duodenal, and stress ulcer. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease: Pathophysiology/diagnosis/management, 5th ed, vol 1. Philadelphia: WB Saunders Co., 1993: 1580-679.
11. Moss S, Calam J. Helicobacter pylori and peptic ulcers: The present position. Gut 1992;33:289-92.
12. Heatley RV. Review article: The treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1992;6:291-303.
13. Hunt RH. pH and Hp - gastric acid secretion and Helicobacter pylori: Implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993;88:481-3.
14. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: A randomized, controlled study. Ann Intern Med 1992;116:705-8.
15. Sung JJY, Chung SCS, Ling TKW, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139-42.
16. Queiroz DMM, Mendes EN, Rocha GA, et al. Effect of Helicobacter pylori eradication on antral gastrin- and somatostatin-immunoreactive cell density and gastrin and somatostatin concentrations. Scand J Gastroenterol 1993;28:858-64.
17. Rangachari PK. Helicobacter and hypergastrinemia: The Quisling option. Scand J Gastroenterol 1991;26(suppl 187):85-90.
18. Freston JW. Overview of medical therapy of peptic ulcer disease. Gastroenterol Clin North Am 1990;19:121-40.
19. Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87:1716-27.
20. Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, doubleblind trial. Am J Gastroenterol 1993;88:1860-4.
21. Graham DY, Opekun AR, Klein PD. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993;16:292-4.
22. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
23. Axon ATR. Campylobacter pylori: Therapy review. Scand J Gastroenterol 1989;24(suppl 160):35-8.
24. Rauws EAJ, Langenberg W, Houthoff HJ, et al. Campylobacter pyloridis-associated chronic active antral gastritis: A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988;94:33-40.
25. Graham DY, Lew GM, Evans DG, et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. Ann Intern Med 1991;115:266-9.
26. Burette A, Glupczynski Y, Deprez C, et al. Lansoprazole plus roxithromycin and metronidazole for eradication of H. pylori: Results of a single-blind pilot study. Acta Gastroenterol BeIg 1993;56(suppl): 131A (abstract).
27. Cayla R, de Mascarel A, Zerbib F, et al. High dose of lansoprazole plus amoxicillin versus high dose of lansoprazole plus amoxicillin and clarithromycin for Helicobacter pylori infection. Gastroenterology 1995;108:A68.
28. Bayerdorffer E, Mannes GA, Sommer A, et al. High-dose omeprazole treatment combined with amoxycillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 1992;4:697-702.
29. Logan RPH, Gummett PA, Schaufelberger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994; 35:323-6.
30. Takimoto T, Taniguchi Y, Yoshida Y, et al. Combination therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. Am J Gastroenterol 1994;89:A415.
31. Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-27.
32. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993;7(suppl 1):13-24.
33. Labenz J, Gyenes E, Ruhl GH, et al. Omeprazole plus amoxicillin: Efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol 1993;88:491-5.
34. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. The Mach l study: Optimal one-week treatment for H. pylori defined? Gut 1995;37(suppl 1):A15.
35. Bell GD, Powell K, Weil J, et al. Experience with omeprazole in combination with either amoxycillin or colloidal bismuth subcitrate in patients with metronidazole-resistant Helicobacter pylori. Eur J Gastroenterol Hepatol 1991;3:923-6.
36. Unge P, Gad A, Eriksson K, et al. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol 1993;5:325-31.
37. Hentschel E, Brandstätter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328: 308-12.
38. Mohamed H, Chiba N, Wilkinson J, et al. Eradication of Helicobacter pylori (Hp): A meta-analysis. Gastroenterology 1994;4:A142.
39. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6.
40. Nagata K, Satoh H, Iwahi T, et al. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: Unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993;37:769-74.
41. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 1993;88:1801 (letter).
42. Rademaker JN, Zettel L, Jacobsen K, et al. Gastric juice immunoglobulins: immunophysiological interactions in Helicobacter pylori infection. Gastroenterology 1993;104:A176.
43. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole. Gastroenterology 1994;106:A172.